There are 594 resources available
337P - Safety and effectiveness of hyper-fractionated simultaneous integrated boost in definitive chemoradiation for limited-stage small cell lung cancer
Presenter: wenqiang guan
Session: Poster Display session
338P - Preoperative immunochemotherapy versus chemotherapy for patients with stage I-IIIB small-cell lung cancer
Presenter: Jiacong Liu
Session: Poster Display session
339P - A retrospective real-world study of neoadjuvant chemotherapy in patients with resectable small-cell lung cancer
Presenter: Wengang Zhang
Session: Poster Display session
340P - Clinical characteristics and survival outcomes in stage I-II small cell lung cancer (SCLC) patients (pts)
Presenter: Marina Puchinskaya
Session: Poster Display session
341P - Efficacy of tumor treating fields (TTFields) in preclinical models of small cell lung carcinoma (SCLC)
Presenter: Uri Weinberg
Session: Poster Display session
342TiP - The PESGA trial: A prospective, open-label, single-arm, phase II study to evaluate first line therapy for ES-SCLC patients, treated by induction carboplatin/etoposide/pembrolizumab followed by maintenance of pembrolizumab/ sacituzumab govitecan
Presenter: Nir Peled
Session: Poster Display session
343TiP - Maintenance therapy with fuzuloparib plus adebrelimab for ES-SCLC after first-line induction with fuzuloparib plus adebrelimab and chemotherapy: A prospective, single-arm, phase II clinical study
Presenter: Huiru Xu
Session: Poster Display session
345TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homologue 3 (B7-H3) protein-targeted antibody-drug conjugate (ADC), in combination with standard of care (SoC), in patients with advanced solid tumours, including lung cancers
Presenter: Hye Ryun Kim
Session: Poster Display session
346P - Multi-omics approach to identify factors underlying antibiotics (ABX)-mediated immunosuppression in a prospective trial of cancer immunotherapy
Presenter: Carolina Alves Costa Silva
Session: Poster Display session